Scarica l'app Stockscreener
38.80
2.86%
1.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$37.72
Aprire:
$37.9
Volume 24 ore:
376.65K
Relative Volume:
0.88
Capitalizzazione di mercato:
$1.88B
Reddito:
$441.33M
Utile/perdita netta:
$9.76M
Rapporto P/E:
194.19
EPS:
0.1998
Flusso di cassa netto:
$839.00K
1 W Prestazione:
+0.60%
1M Prestazione:
+9.88%
6M Prestazione:
-8.94%
1 anno Prestazione:
+69.21%
Intervallo 1D:
$37.90
$39.12
Intervallo di 1 settimana:
$36.51
$39.14
Portata 52W:
$22.22
$48.25
Artivion Inc Stock (AORT) Company Profile
Nome
Artivion Inc
Settore
Industria
Telefono
(770) 419-3355
Indirizzo
1655 ROBERTS BOULEVARD N W, KENNESAW
Compare AORT vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
38.80 | 1.83B | 441.33M | 9.76M | 839.00K | 0.1998 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2025-08-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2025-06-17 | Iniziato | Canaccord Genuity | Buy |
| 2024-10-23 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-27 | Reiterato | Lake Street | Buy |
| 2022-08-08 | Iniziato | Lake Street | Buy |
| 2022-03-03 | Iniziato | Stifel | Buy |
Mostra tutto
Artivion Inc Borsa (AORT) Ultime notizie
Will FDA Approval Of NEXUS And Endospan Option Reshape Artivion's (AORT) Minimally Invasive Aortic Strategy - simplywall.st
Artivion (AORT) Gains Conviction List Spot with Strong Buy Ratin - GuruFocus
Artivion, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
How The Investment Story Is Shifting For Artivion (AORT) After Recent Analyst And FDA Updates - Yahoo Finance
Assessing Artivion (AORT) Valuation After FDA Approval Of NEXUS Aortic Arch System - simplywall.st
Tudor Investment Corp ET AL Sells 39,388 Shares of Artivion, Inc. $AORT - MarketBeat
Ladenburg Thalmann upgrades Artivion (AORT) - MSN
Artivion (NYSE:AORT) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition - MSN
Artivion Inc (AORT) Shares Surge 3.1% -- What GF Score of 85 Tel - GuruFocus
LADENBURG THALM/SH SH Upgrades Artivion (NYSE:AORT) to Buy - MarketBeat
Endospan’s FDA nod for Nexus brings acquisition by Artivion closer - BioWorld News
Growth Value: Is Artivion Inc a momentum stock2026 Growth vs Value & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Artivion secures FDA approval for NEXUS aortic arch system - MSN
Artivion Receives FDA Clearance for NEXUS Aortic Arch System - Bitget
Artivion Secures FDA Approval for NEXUS Aortic Arch System - Zacks Investment Research
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
UnitedHealth, Alignment Healthcare, Humana And Other Big Stocks Moving Higher On Tuesday - Sahm
Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know - Yahoo Finance
Artivion, Inc. (AORT) Stock forecasts - Yahoo Finance UK
Artivion (AORT) Receives "Buy" Rating Reiteration from Needham | - GuruFocus
FDA Greenlights Artivion's (AORT) Nexus Aortic Arch System - GuruFocus
Stocks making big moves yesterday: Levi's, Strategy, Vishay Precision, Celsius, and Artivion - Yahoo Finance
Needham reiterates Artivion stock rating on FDA approval By Investing.com - Investing.com South Africa
Needham reiterates Artivion stock rating on FDA approval - Investing.com
Artivion stock gets FDA approval for NEXUS stent graft system By Investing.com - Investing.com Australia
Artivion stock gets FDA approval for NEXUS stent graft system - Investing.com
FDA approves Artivion’s NEXUS system for aortic arch disease - Investing.com
Needham Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $58 - Moomoo
FDA approves Artivion’s NEXUS system for aortic arch disease By Investing.com - Investing.com South Africa
Artivion Says FDA Approves NEXUS Aortic Arch System, Secures Option to Acquire Endospan - marketscreener.com
Artivion announces U.S. FDA approval of the Nexus® aortic arch system - marketscreener.com
Artivion Announces U.S. FDA Approval Of The Nexus® Aortic Arch System - TradingView — Track All Markets
Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System - ChartMill
Analyst Downgrade: What is the long term forecast for Artivion Inc stockWeekly Profit Analysis & Reliable Breakout Forecasts - baoquankhu1.vn
Why Artivion (AORT) Stock Is Down Today - Yahoo Finance
Artivion Inc (AORT) Trading Down 3.24% on Apr 6 - GuruFocus
SG Americas Securities LLC Raises Stake in Artivion, Inc. $AORT - MarketBeat
Artivion, Inc. (AORT) stock price, news, quote and history - Yahoo Finance UK
Artivion, Inc. (AORT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Holloway Jean F, Artivion SVP, sells $83k in shares - Investing.com
Artivion Inc Com (AORT) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Artivion (NYSE:AORT) Shares Gap DownShould You Sell? - MarketBeat
Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & SuppliesCardiology, Neurology, Vascular Stocks - Yahoo Finance
Artivion Inc Azioni (AORT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):